Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
“All products are sold strictly for research purposes only and are not intended for human consumption. No medical advice is given or implied. Purchasers must be 18 years of age or older. You must agree to these terms and conditions before placing an order.”
Triptorelin is a powerful gonadotropin-releasing hormone (GnRH) agonist peptide primarily used to treat advanced prostate cancer, central precocious puberty, and endometriosis by suppressing sex hormone production (testosterone/estrogen). It works by desensitizing pituitary receptors, causing "chemical castration" to halt hormone-dependent tumor growth.
Key Benefits of Triptorelin:
Prostate Cancer Management: Effective first-line, palliative treatment for advanced, hormone-dependent prostate cancer, often reducing testosterone to castrate levels more reliably than some alternatives.
Central Precocious Puberty (CPP): Stops premature puberty in children, allowing for normal bone development and growth.
Endometriosis and Fibroids: Reduces estrogen, providing relief from symptoms of endometriosis and uterine leiomyoma.
Gender-Affirming Care: Used off-label to suppress testosterone or estrogen in transgender individuals, allowing for better hormone replacement therapy effectiveness.
Reproductive Technology: Used in IVF protocols to prevent premature LH surges.
“All products are sold strictly for research purposes only and are not intended for human consumption. No medical advice is given or implied. Purchasers must be 18 years of age or older. You must agree to these terms and conditions before placing an order.”
Triptorelin is a powerful gonadotropin-releasing hormone (GnRH) agonist peptide primarily used to treat advanced prostate cancer, central precocious puberty, and endometriosis by suppressing sex hormone production (testosterone/estrogen). It works by desensitizing pituitary receptors, causing "chemical castration" to halt hormone-dependent tumor growth.
Key Benefits of Triptorelin:
Prostate Cancer Management: Effective first-line, palliative treatment for advanced, hormone-dependent prostate cancer, often reducing testosterone to castrate levels more reliably than some alternatives.
Central Precocious Puberty (CPP): Stops premature puberty in children, allowing for normal bone development and growth.
Endometriosis and Fibroids: Reduces estrogen, providing relief from symptoms of endometriosis and uterine leiomyoma.
Gender-Affirming Care: Used off-label to suppress testosterone or estrogen in transgender individuals, allowing for better hormone replacement therapy effectiveness.
Reproductive Technology: Used in IVF protocols to prevent premature LH surges.